Seeking Alpha

DexCom, Inc. (DXCM)

  • Aug. 7, 2014, 12:47 PM
  • Aug. 6, 2014, 4:30 PM
    • DexCom (NASDAQ:DXCM): Q2 EPS of -$0.09 beats by $0.01.
    • Revenue of $58.8M (+64.2% Y/Y) beats by $6.35M.
    • Shares +4.6%.
    • Press Release
    | Comment!
  • Feb. 3, 2014, 4:44 PM
    • DexCom (DXCM+5.1% AH after the FDA approves pediatric use of the company’s G4 Platinum continuous glucose monitoring system.
    • The G4 Platinum System, which monitors blood glucose levels in people with diabetes, already had been approved for patients age 18 and older.
    | Comment!
  • Nov. 7, 2013, 1:04 PM
  • Nov. 6, 2013, 5:40 PM
    | Comment!
  • Sep. 27, 2013, 1:57 PM
    • DexCom (DXCM -8.2%) sinks after the FDA approves Medtronic's (MDT +0.2%) MiniMed 530G.
    • Billed as an "artificial pancreas," the device shuts down insulin delivery when it senses blood sugar levels have fallen too low.
    • Both DXCM and Insulet (PODD -2.6%) could have done without the news — the companies market glucose monitors and insulin pumps.
    | Comment!
  • Aug. 8, 2013, 12:49 PM
    | Comment!
  • Aug. 7, 2013, 7:15 PM
    • DexCom (DXCM) moves up on a solid Q2 earnings beat.
    • Product revenue grew 65% Y/Y. Total revenue, which included development grant and other revenue, grew 53% over the same period.
    • Product gross profit totaled $21.8M, compared to $10.6M in Q212.
    • Shares +12.9% AH.
    | Comment!
  • Jun. 13, 2013, 3:46 PM
    Shares of DexCom (DXCM -0.9%) slip today after Feltl & Co. cut the shares to Sell earlier on valuation. The call follows a downgrade to Hold earlier in the week from Wunderlich.
    | Comment!
  • Jun. 10, 2013, 3:35 PM
    DexCom (DXCM -1.7%) slips after Wunderlich's Greg Simpson cut the shares from Buy to Hold on valuation and removed the shares from its Best Ideas List. The firm says the stock is up 65% Y/Y, and, absent a takeover, near/intermediate-term upside on the shares is somewhat limited.
    | Comment!
  • Mar. 12, 2013, 4:02 PM
    DexCom (DXCM +9%) is set to go out near its highs today after director Jay Skyler disclosed he had paid $1.1M to buy 70K shares in the company at $15.50 each. After the transaction, Mr. Skyler now holds 274,036 shares, an increase of 34.3%.
    | Comment!
  • Dec. 29, 2011, 10:32 AM
    DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that growing visibility on the company's Gen4 approval process should push the stock near, or possibly through its $12 price target over the next 12 months.
    | Comment!
  • Nov. 3, 2011, 10:21 AM
    Medical device maker Dexcom (DXCM -13.3%) takes a hit after its Q3 misses across the board, hurt by lagging international sales and higher operational costs. The company says the declining sales trend is likely to continue, and lowers FY11 guidance. It now expects revenue in the range of $62.5M - $67.5M, down from prior estimates of $67.5- $72.5M. Separately, Morgan Keegan cuts the shares to Market Perform off the results.
    | Comment!
Visit Seeking Alpha's
DXCM vs. ETF Alternatives
Company Description
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.